MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection

Author： Gentile Ivan Buonomo Antonio Riccardo Borgia Federico Zappulo Emanuela Castaldo Giuseppe Borgia Guglielmo

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.23, Iss.5, 2014-05, pp. : 719-728

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

Current Medicinal Chemistry, Vol. 21, Iss. 28, 2014-09 ,pp. : 3261-3270

Bentham Science Publishers

Access to resources Recommend Favorite

Telaprevir: A Promising Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

Current Medicinal Chemistry, Vol. 16, Iss. 9, 2009-03 ,pp. : 1115-1121

Bentham Science Publishers

Access to resources Recommend Favorite

Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection

By Sheldon Julie Barreiro Pablo Vincent Vincent

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 8, 2007-08 ,pp. : 1171-1181

Informa Healthcare

Access to resources Recommend Favorite

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection

By Herbst D Alan Reddy K Rajender

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 10, 2013-10 ,pp. : 1337-1346

Informa Healthcare

Access to resources Recommend Favorite

The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity

Current Pharmaceutical Design, Vol. 23, Iss. 30, 2017-11 ,pp. : 4493-4554

Bentham Science Publishers

Access to resources Recommend Favorite